ReviewImmunobiology2012
Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis.
Review in Immunobiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 51 citations in OpenAlex.
- Molecular frontiers in hemodialysis: unraveling the role of membranes in gene expression, epigenetics, and inflammatory pathways.International urology and nephrology · 2025Review
- Pathophysiological changes in patients during hemodialysis and blood reinfusion predict potential development of hemodialysis reactions.Renal failure · 2025Article
- Biocompatibility in hemodialysis: artificial membrane and human blood interactions.BMC nephrology · 2025Review
- Antifouling Zwitterionic Polymer Coatings for Blood-Bearing Medical Devices.Langmuir : the ACS journal of surfaces and colloids · 2025Review
- Unleashing the power of complement activation: unraveling renal damage in human anti-glomerular basement membrane disease.Frontiers in immunology · 2023Review
- Association between the dietary inflammatory index and markers of endothelial and systemic inflammation in hemodialysis patients.Frontiers in nutrition · 2023Article
- Arteriovenous access in hemodialysis: A multidisciplinary perspective for future solutions.The International journal of artificial organs · 2021Review
- Correlations between serum inflammatory markers and comorbidities in patients with end-stage renal disease.Journal of Taibah University Medical Sciences · 2019Article
- Clinical promise of next-generation complement therapeutics.Nature reviews. Drug discovery · 2019Review
- The biocompatibility and bioactivity of hemodialysis membranes: their impact in end-stage renal disease.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2019Review
- Taming hemodialysis-induced inflammation: Are complement C3 inhibitors a viable option?Clinical immunology (Orlando, Fla.) · 2019Article
- Role of the Complement System in the Response to Orthopedic Biomaterials.International journal of molecular sciences · 2018Review
- Synthesis and biocompatibility of an argatroban-modified polysulfone membrane that directly inhibits thrombosis.Journal of materials science. Materials in medicine · 2018Article
- The Complement System in Dialysis: A Forgotten Story?Frontiers in immunology · 2018Review
- The renaissance of complement therapeutics.Nature reviews. Nephrology · 2018Review
- Intradialytic Complement Activation Precedes the Development of Cardiovascular Events in Hemodialysis Patients.Frontiers in immunology · 2018Article
- Effect of the Anti-C1s Humanized Antibody TNT009 and Its Parental Mouse Variant TNT003 on HLA Antibody-Induced Complement Activation-A Preclinical In Vitro Study.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2017Article
- Dietary inflammatory index is associated with serum C-reactive protein and protein energy wasting in hemodialysis patients: A cross-sectional study.Nutrition research and practice · 2016Article
- Complement in disease: a defence system turning offensive.Nature reviews. Nephrology · 2016Review
- New milestones ahead in complement-targeted therapy.Seminars in immunology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Hemodialysis is the most common method used to remove waste and hazardous products of metabolism in patients suffering from renal failure. Hundreds of thousands of people with end-stage renal disease undergo hemodialysis treatment in the United States each year. Strikingly, the 5-year survival rate for all dialysis patients is only 35%. Most of the patients succumb to cardiovascular disease that is exacerbated by the chronic induction of inflammation caused by contact of the blood with the dialysis membrane. The complement system, a strong mediator of pro-inflammatory networks, is a key contributor to such biomaterial-induced inflammation. Though only evaluated in experimental ex vivo settings, specific targeting of complement activation during hemodialysis has uncovered valuable information that points toward the therapeutic use of complement inhibitors as a means to control the unwelcomed inflammatory responses and consequent pathologies in hemodialysis patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.